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 Autism spectrum disorder (ASD) is thought to result from a combination of 
genetic and environmental factors, yet a specific cause remains unknown. In this study, 
exposure and outcome data from a South Korean cohort (N=3,711) were analyzed to 
investigate the possibility of an environmental contribution to autism etiology. No 
significant association was observed between use of prenatal medications and autistic 
behaviors, as measured by Korean versions of both the Autism Spectrum Screening 
Questionnaire (ASSQ; OR 1.20, 95% CI 0.95–1.51) and the Social Responsiveness Scale 
(SRS; OR 0.98, 95% CI 0.78–1.25). Similarly, no significant associations were observed 
when use of prenatal vitamins, folic acid, or iron supplements was examined. There was 
also no dose-response relationship observed between number of medications taken during 
pregnancy and increased autistic behaviors. No evidence for a role of prenatal medication 
use in autism etiology is suggested by the data in this study. Future investigations 
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Table 1. Characteristics of study participants according to prenatal medication status. 
 Exposure statusa  
Characteristic 
Took any prenatal 
medication 
(N=1,656)b 
Did not take any prenatal 
medication (N=1,885)b pc 
Maternal education   <0.001 
<12 years 54 (3.7) 89 (5.9)  
12 years 789 (54.7) 906 (60.1)  
>12 years 600 (41.6) 512 (34.0)  
    
Paternal education   <0.001 
<12 years 53 (3.7) 75 (4.9)  
12 years 608 (42.1) 745 (48.8)  
>12 years 785 (54.3) 708 (46.3)  
    
Monthly family income   <0.001 
<1M KW 65 (4.1) 146 (8.4)  
1–<2M KW 237 (15.1) 328 (18.9)  
2–<3M KW 510 (32.5) 551 (31.8)  
3–<4M KW 367 (23.4) 380 (21.9)  
4–<5M KW 243 (15.5) 184 (10.6)  
≥5M KW 147 (9.4) 145 (8.4)  
    
Maternal smoking 
during pregnancy 
  0.145 
Yes 5 (0.4) 12 (0.8)  
No 1433 (99.7) 1513 (99.2)  
    
Family history of ASD   0.122 
Yes 33 (2.0) 25 (1.3)  
No 1613 (98.0) 1843 (98.7)  
    
Disease during 
pregnancy 
  0.003 
Yes 148 (11.1) 116 (7.9)  
No 1183 (88.9) 1355 (92.1)  
    
Child’s sex   0.121 
Male 808 (48.8) 969 (51.4)  
Female 848 (51.2) 916 (48.6)  
    
Premature birth   0.692 
Yes 68 (4.8) 67 (4.4)  
No 1364 (95.3) 1441 (95.6)  
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Parity   <0.001 
1st child 845 (54.7) 725 (42.5)  
2nd child 579 (37.5) 749 (43.9)  
≥3rd child 120 (7.7) 234 (13.7)  
    
Gestational age at birth   <0.001 
≤31 weeks 9 (0.6) 40 (2.3)  
32-36 weeks 225 (14.0) 221 (12.7)  
37-41 weeks 1171 (73.0) 1211 (69.6)  
≥42 weeks 200 (12.5) 268 (15.4)  
a. Values are N (%) for categorical variables. 
b. Column percentages may not sum to 100 due to missing data and rounding. 


































Table 2. Description of the sample population, by prenatal medication (N=3,711). 
Prenatal medication N (%)a 
Any medication  
Yes 1656 (44.6) 
No 1885 (50.8) 
  
Hyperemesis  
Yes 172 (4.6) 
No 3369 (90.8) 
  
Hypertension  
Yes 9 (0.2) 
No 3532 (95.2) 
  
Folic acid  
Yes 85 (2.2) 
No 3459 (93.2) 
  
Iron  
Yes 1551 (41.8) 
No 1990 (53.6) 
  
Alternative  
Yes 77 (2.1) 
No 3464 (93.3) 
  
Pain  
Yes 32 (0.9) 
No 3509 (94.6) 
  
Prenatal vitamins  
Yes 106 (2.9) 
No 3435 (92.6) 
  
Other  
Yes 42 (1.1) 
No 3669 (98.8) 










Table 3. Associations between ASSQ and SRS measures and prenatal medication use.  
 No. (%) of Participants  
Outcome measure 
Used any prenatal 
medication 
(N = 1,656)a 
Did not use any prenatal 
medication 
(N = 1,885)a pb 
ASSQ total score   0.919 
High ASD  
likelihood 
(ASSQ ≥ 15) 
 
80 (4.9) 94 (5.0)  
Intermediate ASD 
likelihood 
(10 ≤  ASSQ < 15) 
 
124 (7.5) 135 (7.2)  
Low ASD  
likelihood  
(ASSQ < 10) 
1445 (87.6) 1645 (87.8)  
    
SRS T-score    0.237 
High ASD  
likelihood 
(SRS ≥ 76) 
 
19 (1.2) 27 (1.5)  
Intermediate ASD 
likelihood 
(60 ≤  SRS < 76) 
 
167 (10.2) 218 (11.7)  
Low ASD  
likelihood 
(SRS < 60) 
1456 (88.7) 1612 (86.8)  
a. Column percentages may not sum to 100 due to missing data and rounding. 
















Table 4. Crude and adjusted effect of prenatal medication use on ASSQ and SRS scores, 
ordinal logistic regression. 
 Odds Ratio (95% Confidence Interval) 
Outcome measure Used any prenatal 
medication 
Did not use any prenatal 
medication 
ASSQ total score   
Crude 1.01 (0.83–1.24) 1.00 
Adjusteda 1.20 (0.95–1.51) 1.00 
Adjustedb 1.04 (0.85–1.28) 1.00 
   
SRS T-score   
Crude 0.84 (0.69–1.03) 1.00 
Adjustedc 0.98 (0.78–1.25) 1.00 
Adjustedd 0.89 (0.72–1.10) 1.00 
a. Adjusted for child’s sex and maternal education. 
b. Multiple imputation model; Adjusted for child’s sex and maternal education. 
c. Adjusted for child’s sex, paternal education, and premature birth. 




Table 5. Crude and adjusted effect of prenatal vitamin, folic acid, or iron supplement use 
on ASSQ and SRS scores, binary logistic regression. 
 Odds Ratio (95% Confidence Interval) 
Outcome measure 
Used prenatal vitamins, 
folic acid, or iron Did not use medication 
ASSQ total score ≥10   
Crude 0.98 (0.79–1.22) 1.00 
Adjusteda 0.99 (0.80–1.22) 1.00 
   
SRS T-score ≥60   
Crude 0.72 (0.58–0.90) 1.00 
Adjustedb 0.87 (0.68–1.13) 1.00 
a. Adjusted for child’s sex. 












Table 6. Crude and adjusted effect of any prenatal medication use (excluding vitamins, 
folic acid, or iron supplements) on ASSQ and SRS scores, binary logistic regression. 
 Odds Ratio (95% Confidence Interval) 
Outcome measure 
Used medication other 
than vitamins, folic acid, 
or iron Did not use medication 
ASSQ total score ≥10   
Crude 1.72 (1.00–2.97) 1.00 
Adjusteda 1.72 (1.00–2.97) 1.00 
   
SRS T-score ≥60   
Crude 1.33 (1.42–1.82) 1.00 
Adjustedb 1.55 (0.79–3.02) 1.00 
a. All covariates were removed during backward elimination. 





























Table 7. Crude and adjusted effect of number of prenatal medications taken on ASSQ and SRS scores, binary 
logistic regression. 
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SRS T-
score ≥60 
     0.249 


















a. Adjusted for child’s sex and maternal education. 
b. Adjusted for child’s sex, paternal education, and premature birth. 




 Autism spectrum disorder is a complex neurodevelopmental disorder marked by 
deficits in social communication, as well as in restrictive and repetitive behaviors (APA, 
2013). The prevalence of ASD has risen dramatically in recent years. According to the 
Centers for Disease Control and Prevention’s (CDC) Autism and Developmental 
Disabilities Monitoring (ADDM) Network, analysis of data from 2010 reveals that ASD 
affects 1 in 68 (~1.5%) children in the United States (Developmental, 2014). Results 
from the National Survey of Children’s Health (NSCH) reveal that the parent-reported 
prevalence of ASD in children ages 6 to 17 increased from 1.16% in 2007 to 2.00% in 
2011–2012 (Blumberg et al., 2013). Observed increases in ASD prevalence have not 
been restricted to the United States. Idring and colleagues (2014) investigated the 
prevalence of ASD in the Stockholm Youth Cohort (SYC), finding a change in 
prevalence among children ages 0 to 17 from 0.42% in 2001 to 1.44% in 2011. In 
addition, ASD prevalence has been measured at greater than 2% in South Korean samples 
(Kim et al., 2011).  
ASD is thought to be among the most genetic of neuropsychiatric disorders 
(Miles, 2011; O’Roak & State, 2008; Rutter et al., 1999). Early twin studies provided the 
foundation for this notion, calculating the disorder’s heritability at above 90% and 
demonstrating a large difference in concordance rate between monozygotic and dizygotic 
twins (60%-90% vs. <5%; Rutter et al., 1999). The largest and most recent ASD twin 
study, from a group in Sweden, has also supported the idea of a strongly genetic 
component, calculating a relative recurrence risk (RRR) of ASD of 153.0 (95% 
confidence interval [CI] 56.7–412.8) among monozygotic twins and observing an 
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increasing RRR with increasing genetic relatedness (Sandin et al., 2014). However, to 
date only 20% of all cases of ASD have been explained by inherited genetic variants 
(Miles, 2011). The Swedish twin study recently estimated the heritability—the proportion 
of phenotypic variability attributable to genetic variation—of ASD to be 0.50 (95% CI 
0.45–0.56), and the contribution of non-shared environmental influence was estimated at 
0.50 (95% CI 0.44–0.55). Thus, while the cause of ASD is likely to have a strongly 
genetic component, there is still a possibility that environmental factors acting directly or 
through gene-environment interactions may contribute substantially to ASD etiology. 
Over the years, several studies have attempted to elucidate the relationship 
between medication use during pregnancy and development of autism in offspring. In the 
first meta-analysis of the relationship between prenatal factors and ASD risk, Gardener 
and colleagues (2009) identified fifteen studies that examined prenatal medication use 
and determined that maternal use of any medication during pregnancy was associated 
with a 46% increased risk of ASD (95% CI 8%–96%). Maimburg and Vaeth (2006) 
conducted a case-control study examining the associations between a variety of 
exposures and infantile ASD. Data on prenatal medication use was obtained from Danish 
medical birth records for approximately 460 cases and 460 controls. After adjusting for 
parental ages, maternal citizenship, birth weight, gestational age, Apgar score, and birth 
defects, the authors found that children of mothers who took medications during 
pregnancy had an odds ratio (OR) of 1.5 (95% CI 1.1–2.1) compared to children of 
mothers who did not take medications, although the authors did not specify which classes 
of medication were included in their analyses (Maimburg & Vaeth, 2006). In contrast to 
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these studies, an earlier review of seven studies did not report an association between 
prenatal medication use and autism or autistic traits (Kolevzon et al., 2007).  
 Other studies have focused on various types of medications and supplements. In a 
rodent model of autism, a Korean group demonstrated that prenatal administration of 
Korean red ginseng extract—a traditional Korean medicine—inhibited valproate-induced 
hyperactivity and decreased sociability in the offspring (Kim et al., 2013). Several studies 
have investigated associations between prenatal folic acid use and ASD. Steenweg-de 
Graaff and colleagues (2014) observed in a prospective study that maternal folate plasma 
concentration during pregnancy was not associated with autistic traits in children. 
However, this group also observed that children of mothers who used prenatal folic acid 
supplements had lower autistic traits scores, as measured by the Social Responsiveness 
Scale (SRS), compared to children of mothers who did not use such supplements 
(p<0.001; Steenweg-de Graaff et al., 2014). In an analysis of over 97,000 individuals 
enrolled in the Norwegian Mother and Child Cohort (MoBa), Surén and colleagues 
(2013) examined use of folic acid supplements from four weeks before to eight weeks 
after the start of pregnancy. Exposure assessment occurred via a postal questionnaire 
administered at gestation week 18 and a food frequency questionnaire administered at 
gestation week 22. After adjusting for year of birth, maternal education level, and parity, 
the authors found that children of mothers who took folic acid had decreased odds of 
being autistic compared to children of mothers who did not take folic acid (OR 0.61, 95% 
CI 0.41–0.90; Surén et al., 2013). Schmidt et al. (2012) examined folic acid as an 
exposure in an analysis of participants from the Childhood Autism Risks from Genetics 
and Environment (CHARGE) study. Mean folic acid intake was significantly greater in 
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the first month of pregnancy for typically developing children (N=278) compared to 
children with ASD (N=429). In comparison with children whose mothers reported taking  
<600 𝜇g/day of folic acid, children whose mothers took ≥600 𝜇g/day had an ASD OR of 
0.62 (95% CI 0.42–0.92). Folic acid intake was then categorized into quintiles, and a 
significant trend (p=0.01) was observed for decreasing risk of ASD as folic acid intake 
increased, controlling for maternal education level and child’s birth year. However, this 
trend was rendered non-significant after also adjusting for intake of vitamins A, B6, C, 
and D.  
 The CHARGE study has also yielded insight into the relationship between 
prenatal vitamin use and ASD (Schmidt et al., 2011). In a 2011 study, prenatal vitamin 
exposure was assessed retrospectively through phone interviews. After adjusting for 
maternal education and the child’s birth year, children of women who used prenatal 
vitamins three months before pregnancy through one month after conception had reduced 
odds of ASD compared to children whose mothers did not use prenatal vitamins during 
this time period (OR 0.62, 95% CI 0.42–0.93). In an analysis of data from the Health 
Outcomes and Measures of the Environment (HOME) study, mothers were interviewed 
during pregnancy about second trimester prenatal vitamin use, and autistic behaviors 
were later measured in enrolled children at ages 4 and 5 using the SRS (Braun et al., 
2014). Compared to children of women who reported using prenatal vitamins weekly or 
daily, children of women who reported using them never or rarely had reduced odds of 
having a T-score ≥60 (reflecting autistic behaviors of mild to moderate severity) on the 
SRS after adjusting for a variety of prenatal and demographic variables.  
 16 
 Finally, prenatal use of antidepressant and antiepileptic drugs has received 
increased attention as an exposure that may be related to autism. A prospective study 
conducted with participants in the MoBa cohort reported that children exposed to 
antiepileptic drugs in utero yielded a 3.4-fold increased risk (95% CI 1.6–7.0) of the child 
having autistic traits, compared to unexposed children, as measured by the Social 
Communication Questionnaire (SCQ) and adjusting for several maternal and child factors 
(Veiby et al., 2013). Croen and colleagues (2011) observed that children of mothers in a 
Northern California population who took selective serotonin reuptake inhibitors (SSRIs) 
during the first trimester had a 3.5-fold increased risk (95% CI 1.5–7.9) of ASD 
compared to unexposed children after controlling for age, race, education, and other 
factors. Highlighting the lack of consensus regarding the role played by medication use in 
the etiology of ASD, numerous studies have failed to find an association between 
prenatal antidepressant use and ASD, some employing the same cohorts as studies that 
reported positive associations (Hviid et al., 2013; Sørensen et al., 2013; Clements et al., 
2014).  
 Previous studies have yielded mixed findings regarding the association between 
prenatal medication use and ASD. Different methodologies have been used to assess 
differing exposures and outcomes in various populations. Thus, there remains a need for 
further investigation to build upon these earlier investigations in determining whether 
prenatal use of medications and supplements contributes to risk for ASD. If prenatal 
medication use were ultimately shown to impart ASD risk in several disparate 
populations, then there would be strong evidence for a true association between 
medication use and ASD occurrence. Further, if such an association exists, then there are 
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two important opportunities: 1) a potential role for gene-environment interactions (GxE) 
or fetal programming in the etiology of ASD, and 2) the possibility of a preventive 
intervention that alters the use of these medications during pregnancy. GxE are defined 
by genetic differences in vulnerability to specific environmental factors that contribute to 
a phenotype (Kim & Leventhal, 2015), while fetal programming of adult health states 
takes place when normal patterns of fetal growth are disrupted due to unfavorable 
conditions in utero (Pollard, 2007). Both of these influences on adult phenotype are 
important avenues through which medication use may affect autism risk if a true 
association exists.   
This study is intended to inform future research investigating environmental 
factors in utero that may play a role in the etiology of autism. Equipped with a large 
sample size and the ability to incorporate a number of potential confounding variables, 
the present study is, to our knowledge, the first analysis of the association between 
prenatal medication use and autistic traits in a South Korean cohort. 
Materials and Methods 
 
Study population 
This study is a secondary analysis of de-identified data from the Children’s Health 
and Environmental Research (CHEER) study, an effort to examine associations between 
environmental agents and health outcomes affecting South Korean children. The CHEER 
study is sponsored by the Korean Ministry of the Environment, and a detailed description 
of this research effort is found in Ha et al., 2009. Briefly, from 2005 to 2007, 6,722 five- 
to fourteen-year-old students from 22 public schools in 10 South Korean locations (3 
metropolitan, 4 industrialized, and 3 rural) were recruited for evaluation in the ongoing 
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CHEER study. From the original cohort, 5,293 students (79%) completed follow-up 
evaluations in 2007 and 2008, during which environmental exposure data were collected 
and blood and urine testing, perinatal risk evaluations, and physical exams were 
performed. The 40 cc of blood collected from each individual was stored at -70oC in the 
biorepository at Dankook University. This follow-up sample was 51.5% male and had a 
mean age of 7.3±1.0 years. Of this sample, 3,804 agreed to participate in the CHEER 
gene-environment interaction study. After excluding 93 participants who self-reported 
use of unspecified “weight gain” medications, these individuals formed our study sample 
for the present analyses. 
Exposure ascertainment 
 The primary exposure measure was use of any of seven classes of medication 
during pregnancy. The medications included were folic acid, hypertension medication, 
hyperemesis medication, iron supplements, alternative medicines, pain medication, or 
prenatal vitamins. In separate survey items, mothers of participating children were asked 
to recall whether they had taken these medications during pregnancy. Use of any prenatal 
medication was defined as responding “yes” to any of these items or writing in a different 
medication in a free-response field. 
Outcome ascertainment 
 The two main outcome variables were parent-rated Autism Spectrum Screening 
Questionnaire (ASSQ) total score and parent-rated Social Responsiveness Scale (SRS) T-
score. The ASSQ is a parent- or teacher-completed checklist useful for identification of 
Asperger’s and other high-functioning ASD in children and adolescents with normal 
intelligence or mild intellectual disability (Ehlers et al., 1999). The questionnaire consists 
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of 27 items, each inquiring whether the child stands out as different from other children 
of his or her age in some way. Responses are rated on a scale from 0 (no) to 2 (yes). For 
the present analysis, it was decided that a cutoff score of ≥15 was reasonable for high 
likelihood of ASD based on the notion that this score represented 76% sensitivity and 
81% specificity for detecting ASD (Ehlers et al., 1999). Consequently, ASSQ scores in 
the range of 10 to 14 were selected to indicate social impairment as a proxy for 
intermediate likelihood of having ASD. While the ASSQ has yet to be validated in South 
Korean populations, it has been translated into Korean and used in previous autism 
research in that country (Kim et al., 2011). 
The SRS is a parent- or teacher-completed questionnaire designed to assess a 
child’s ability to engage in reciprocal social interaction (Constantino et al., 2003). The 
questionnaire consists of 65 items, each rating an observed aspect of social behavior on a 
numeric scale from 1 (never true) to 4 (almost always true). Interpretation is based on a 
single score reflecting the sum of all 65 responses, which is converted to a standardized 
T-score. A T-score between 60 and 75 places the child within the mild to moderate range, 
suggesting that the child has mild or high-functioning ASD. A T-score of 76 or higher 
places the child within the severe range, as these scores are strongly associated with an 
ASD diagnosis (Constantino & Gruber, 2005). The CHEER study employed the Korean 
version of the SRS. 
Statistical analysis 
 All statistical analyses were conducted using SAS, version 9.4 software via the 
SAS Studio interface, version 3.3 (SAS Institute Inc., Cary, NC). Crude associations 
between the exposure of interest and covariates were conducted with the chi-square test. 
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The crude and adjusted relationships between prenatal use of any medication and ASSQ 
and SRS scores were examined using ordinal logistic regression models. The following 
covariates were examined as potential confounders of these associations: parent-reported 
maternal education, paternal education, monthly family income, maternal smoking during 
pregnancy, family history of ASD, maternal disease during pregnancy, child’s sex, 
premature birth, gestational age at birth, and parity. The majority of these covariates were 
included on the basis of having been incorporated into previous analyses of relationships 
between prenatal medication use and ASD (Braun et al., 2014; Schmidt et al., 2011; 
Schmidt et al., 2012; Surén et al., 2013). Disease during pregnancy was defined as having 
any of gestational diabetes, pregnancy-related hypertension, pre-eclampsia, thyroid 
disease, appendicitis, asthma, atopy, or any self-reported disease during the prenatal 
period. We arrived at the final logistic regression models via backward elimination of 
covariates. Covariates that remained significant at the 0.05 level for the Wald chi-square 
test were retained. In crude and adjusted analyses, complete case analysis was performed. 
Power was greater than 90% to detect a true odds ratio of 1.5 (Appendix). Sensitivity 
analyses using multiple imputation were constructed to assess the impact of missing data. 
In secondary analyses, the crude and adjusted impact of folic acid, prenatal vitamin, or 
iron supplement use vs. medication non-use, as well as the impact of the number of 




 This study sample consisted of 3,711 mother-child pairs, which is approximately 
55% of the original CHEER cohort. Data on the primary exposure of prenatal use of any 
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medication were missing for 170 (4.6%) participants. Mothers who took any prenatal 
medication tended to have had a disease during pregnancy, and they also tended to be 
more highly educated and wealthier (Table 1). Compared to mothers who took prenatal 
medications, mothers who did not take any prenatal medications did not differ 
significantly with respect to smoking status, family history of ASD, giving birth 
prematurely, or child’s sex.  
Prenatal medication intake 
 Use of any medication during pregnancy was reported by 1,656 mothers (44.6%) 
in the study sample (Table 2). Iron supplements were the most common medication 
reported, with over 40% of prenatal medication users reporting iron supplement use. By 
contrast, hypertension medication use was least prevalent in the sample, with only 0.2% 
of those who took medications reporting its use. As shown in Table 3, prenatal use of any 
medication did not have a significant association with either ASSQ total score or SRS T-
score, as measured by the chi-square test. The distribution of ASD likelihood as 
measured by both parent-rated ASSQ and parent-rated SRS was similar between children 
of mothers who did and did not use medications during pregnancy.  
 The crude and adjusted effects of prenatal medication use on ASSQ and SRS 
scores are shown in Table 4. In the unadjusted analysis, use of any prenatal medication 
was not predictive of an increased ASSQ score compared to non-use of prenatal 
medication. After adjusting for child’s sex and maternal education, the OR for this 
association increased slightly but remained non-significant at 0.05 level (OR 1.20, 95% 
CI 0.95–1.51). Similarly, use of any prenatal medication was not predictive of an 
increased SRS score compared to non-use of prenatal medications in the unadjusted 
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analysis. After adjusting for child’s sex, paternal education, and premature birth, the 
association remained non-significant (OR 0.98, 95% CI 0.78–1.25). Sensitivity analyses 
with imputed values for all variables in the adjusted analyses were also non-significant, 
although these effect estimates did not pass the score test for the proportional odds 
assumption and may thus be inaccurate estimates. 
 In the secondary analyses, children of mothers who used prenatal vitamins, folic 
acid, or iron supplements were no more likely to have an ASSQ score of 10 or greater 
compared to children of mothers who did not report prenatal medication use (Table 5; OR 
0.99, 95% CI 0.80–1.22). Despite the observation of a protective effect in the crude 
analysis, children of mothers who took prenatal vitamins, folic acid, or iron supplements 
were not significantly more likely to have an SRS T-score of 60 or more in comparison to 
children of mothers who did not use medications in the adjusted analysis (OR 0.87, 95% 
CI 0.68–1.13). Conversely, in crude analyses, children of women who used any 
medication other than vitamins, folic acid, or iron supplements were more likely to have 
both an ASSQ score ≥10 and an SRS T-score ≥60 (Table 6). Attempts to adjust for 
covariates did not alter the ASSQ OR, but the SRS OR was rendered non-significant 
following adjustment for child’s sex, paternal education, and premature birth. Finally, no 
dose-response relationship between number of medications taken and risk of autistic 
behaviors was observed (Table 7). One odds ratio in the crude analysis was marginally 
significant at the 0.05 level, but no effect estimates in the adjusted analyses were 
significant. Slight dose-response trends were observed correlating higher scores of 
autistic behavior with increasing number of medications taken, particularly in the SRS 
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Prenatal medication intake 
 In this study of a South Korean cohort, no significant associations were found 
between prenatal medication use and ASSQ total score, as well as between prenatal 
medication use and SRS T-score. To our knowledge, this is the first study that has 
investigated these associations in a South Korean population. Assuming that the 
prevalence of autism in this Korean population is similar to that calculated by Kim and 
colleagues (2.64%), this study had sufficient power to detect an OR of 1.5 for children of 
exposed vs. unexposed mothers (Appendix). However, a much larger study sample would 
be necessary to detect a significant effect estimate if the true OR is more moderate than 
1.5. An OR of 1.5 was chosen for our power calculations based on the ORs of 1.46 and 
1.50 observed by Gardener et al. (2009) and Maimburg & Vaeth (2006), respectively, in 
their assessments of the relationship between any prenatal medication use and ASD.  
Sensitivity analyses employing multiple imputation of the variables included in the 
adjusted analysis did not substantially impact the ORs reported in Table 4.  
Several of the covariates used in the main analyses had non-trivial amounts of 
missing data. For the adjusted ASSQ analysis in Table 4, 799 (20.9%) subjects were 
excluded due to missing data, while 873 (23.5%) subjects were excluded from the 
adjusted SRS analysis. Assuming non-differential misclassification of missingness, this 
phenomenon would be expected to bias the results toward the null, which could explain 
in part our non-significant effect estimates. Additionally, if mothers who took prenatal 
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medications are biologically different from mothers who did not take such medications, 
our results could be impacted by confounding by indication. In other words, the child’s 
risk of autism could be influenced by the conditions that caused the mothers to take 
medications, rather than the medications themselves. Small numbers of subjects reporting 
certain medications, such as hypertension and pain medications, necessitated the use of a 
composite primary exposure variable and precluded substantial secondary analyses 
investigating medication subtypes. If such subgroup analyses had been possible, it might 
have been clearer as to which medications may impart the greatest risk of autism to 
offspring in this population.  
Previous studies have suggested that use of prenatal vitamins and folate may 
confer protective effects against autism development to the fetus (Braun et al., 2014; 
Schmidt et al., 2011; Schmidt et al., 2012). Our secondary analyses of this relationship 
did not agree with these studies, as we observed in our adjusted analyses no significant 
association between maternal prenatal vitamin, folic acid, or iron supplement use and 
both outcome measures (Table 5). Iron supplements were included in this composite 
exposure variable because, like prenatal vitamins and folic acid, these supplements are 
taken as part of routine prenatal care rather than for a specific condition requiring 
treatment. These analyses were also impacted by missing data to roughly the same extent 
as the primary analyses. For the adjusted ASSQ analysis in Table 5, 472 (12.7%) subjects 
were excluded due to missing data, and 1,107 (29.8%) subjects were excluded from the 
adjusted SRS analysis. The analyses in Table 6 show the converse of those in Table 5. 
Use of any medication other than vitamins, folic acid, or iron supplements was shown to 
be borderline significant with an increased ASSQ score, while a non-significant OR was 
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observed in the SRS analysis. We hypothesized that, in contrast to the medications in 
Table 5, these medications might place children at increased risk of autistic behaviors. 
While we did observe ORs above 1.0, they were not significant at the 0.05 level. It is 
possible that, with a larger sample size, a significant effect might have been observed. 
In the final secondary analyses, no significant trend relating increased prenatal 
medication intake to higher ASSQ and SRS scores was observed (Table 7). The wide CIs 
for some cells are indicative of the imprecision of these calculations, as cell sizes for 
those reporting the highest usage of medication were small. Few people reported taking 
more than four medications during pregnancy, so it was necessary to collapse these 
individuals into a single category of high medication intake so that the cell sizes would be 
large enough to conduct these analyses. Similarly, binary logistic regression was chosen 
over ordinal logistic regression for all secondary analyses, as the cell sizes would have 
been too small to permit meaningful calculations.  
Study strengths and limitations 
 The large sample size in this study allowed for precise effect estimates in the 
primary analyses. Also, substantial covariate data allowed for the inclusion of numerous 
potential confounders in the adjusted analyses. Use of multiple measurements of autistic 
behaviors permitted us to examine the effect of medication use on disparate components 
of the autism phenotype. However, retrospective self-report of exposure information 
invites the possibility of recall bias. Mothers in this study were asked to provide exposure 
information from several years in the past, and recall accuracy was likely an issue for 
many participants. In some cases, mothers could have been recalling exposure 
information after their children had already been formally diagnosed with ASD, and these 
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mothers might have been more inclined than mothers of children without autism to report 
prenatal medication use, thinking it a potential cause of autism. At the same time, the 
total number of children scoring in the high-risk ranges of the ASSQ and SRS is small, so 
any recall bias is likely to be non-differential, skewing our results toward the null. The 
results in our analyses were also plagued by substantial missing data for several 
covariates. For almost all of our complete case analyses, more than one-fifth of all 
subjects were excluded due to missing data. These missing data impair our ability to 
generalize the results of this study to the rest of the CHEER cohort, as our study sample 
may not be wholly representative of the study population. 
 We are also limited by a lack of information on the frequency and dosage of 
prenatal medications to which women in the cohort were exposed. It is possible that 
prenatal medication use could confer autism risk only during particular stages of 
pregnancy, and previous studies have observed significant associations between use of 
specific medications during particular trimesters and ASD risk (Croen et al., 2011; 
Gidaya et al., 2014). However, women in the current study only self-reported any use of 
prenatal medications rather than use during specific intervals, so stratification by 
trimester was not possible. The lack of dosage information precluded the ability to test 
whether higher doses of specific medications might confer higher risk of ASD to the 
offspring. For almost all of the seven broad classes of medication examined in this study, 
the prevalence of use was too small to permit subgroup analyses that would have allowed 
us to examine the separate effects of different classes of medication. It is likely that the 
dosage of specific types of medication taken during pregnancy, rather than the total 
number of different medications taken, is of great importance in elucidating the 
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relationship between medication use and ASD risk, yet we were unable to investigate this 
area further in this study. This consideration is especially important in relation to 
potential opportunities for GxE as well as fetal programming. Different subtypes of 
prenatal medication, and even different medications within those subtypes, can exert 
disparate effects on the developing fetus. An inability to study medication subtypes 
makes it difficult to form plausible biological mechanisms for the potential effect of 
prenatal medications on autism development via GxE or fetal programming. 
Although a number of previous studies have examined use of any prenatal 
medication as a risk factor for ASD (Gardener et al., 2009; Maimburg & Vaeth, 2006), 
not all of these studies specified the precise subclasses of medications that were included 
under the catch-all of “any medication use.” This lack of detailed information makes it 
difficult to directly compare the results of this study with previous work. For example, 
the CHEER cohort did not contain information about use of psychiatric medication such 
as antidepressants, whereas Gardener and colleagues in their review identified this 
subclass of medications as one that might put children at an increased risk of ASD 
compared to just “any medication use” (Gardener et al., 2009).   
 Finally, outcome assessment in this sample population was conducted using tools 
that screen for autistic behaviors rather than those that form the gold standard in autism 
diagnosis. Our analysis thus assessed the risk of having a high score on either the ASSQ 
or SRS rather than receiving a clinical ASD diagnosis via the Autism Diagnostic 






Though subject to various limitations as noted above, our data do not suggest an 
association between prenatal medication use and risk of autistic behaviors in this South 
Korean population. Given the disagreement between these results and those of previous 
studies, especially with regard to prenatal vitamin and folic acid use, further study with 
improved exposure assessment is warranted in order to clarify any relationship between 
prenatal medication use and autism that may exist. Such a relationship would provide 
evidence for an environmental contribution to autism risk, which could enable an avenue 
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Ordinal logistic regression power calculations 
 
Adapted from: 
Whitehead, J. (1993). Sample size calculations for ordered categorical data. Statistics in Medicine, 12(24), 
2257–2271. doi:10.1002/sim.4780122404 
OR of 1.5 
 
Table A1. 
No prenatal meds C1 – low likelihood 
ASD (ASSQ or 
SRS) 
C2 – intermediate 
likelihood ASD 
(ASSQ or SRS) 
C3 – high likelihood 
ASD (ASSQ or 
SRS) 
p(iC) 0.9236 0.05 0.0264a 
Q(iC) 0.9236 0.9736 1 
a. Prevalence estimate from Kim et al., 2011 
 












0.9236+ 1− 0.9236 𝑒!.!"# = 0.88828 
 
Table A2. 
Prenatal meds C1 – low likelihood C2 – int. likelihood C3 – high likelihood 
p(iER) 0.88828 0.07212 0.0396a 
Q(iER) 0.88828 0.9604 1 
a. Assumes that, if prenatal use of any medication does increase the likelihood of having 
a child with ASD, among those exposed to any medication, probability of being in high 




 C1 – low likelihood C2 – int. likelihood C3 – high likelihood 
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 = 0.0660 
 
 
Fig. A3. Equation for total N required 
 












−0.419 !(0.254) = 2824.9 = 2825 = 1413  𝑝𝑒𝑟  𝑔𝑟𝑜𝑢𝑝 
 
 
OR of 1.25 
 
Table A4. 
No prenatal meds C1 – low likelihood 
ASD (ASSQ or 
SRS) 
C2 – intermediate 
likelihood ASD 
(ASSQ or SRS) 
C3 – high likelihood 
ASD (ASSQ or 
SRS) 
p(iC) 0.9236 0.05 0.0264a 
Q(iC) 0.9236 0.9736 1 
a. Prevalence estimate from Kim et al., 2011 
 













0.9236+ 1− 0.9236 𝑒!.!"# = 0.9057 
 
Table A5. 
Prenatal meds C1 – low likelihood C2 – int. likelihood C3 – high likelihood 
p(iER) 0.9057 0.0613 0.033a 
Q(iER) 0.9057 0.967 1 
a. Assumes that, if prenatal use of any medication does increase the likelihood of having 
a child with ASD, among those exposed to any medication, probability of being in high 
likelihood group is 1.25 times that of the unexposed group. 
 
Table A6. 
 C1 – low likelihood C2 – int. likelihood C3 – high likelihood 
𝑝! !.!"#$!!.!"#$
!
 = 0.9147 !.!"!!.!"#$
!
 = 0.05565 !.!"#$!!.!""
!
 = 0.0297 
 
 
Fig. A6. Equation for total N required 
 




−0.230 !(0.234) = 7585 = 3793  𝑝𝑒𝑟  𝑔𝑟𝑜𝑢𝑝 
 
 
 
